Year: 2019
Type: article
Abstract: The bicyclic boronate VNRX-5133 (taniborbactam) is a new type of β-lactamase inhibitor in clinical development. We report that VNRX-5133 inhibits serine-β-lactamases (SBLs) and some clinically important metallo-β-lactamases (MBLs), including NDM-1 and VIM-1/2. VNRX-5133 activity against IMP-1 and tested B2/B3 MBLs was lower/not observed. Crystallography reveals how VNRX-5133 binds to the class D SBL OXA-10 and MBL NDM-1. The crystallographic results highlight the ability of bicyclic boronates to inhibit SBLs and MBLs via binding of a tetrahedral (sp3) boron species. The structures imply conserved binding of the bicyclic core with SBLs/MBLs. With NDM-1, by crystallography, we observed an unanticipated VNRX-5133 binding mode involving cyclization of its acylamino oxygen onto the boron of the bicyclic core. Different side-chain binding modes for bicyclic boronates for SBLs and MBLs imply scope for side-chain optimization. The results further support the “high-energy-intermediate” analogue approach for broad-spectrum β-lactamase inhibitor development and highlight the ability of boron inhibitors to interchange between different hybridization states/binding modes.
Source: Journal of Medicinal Chemistry
Language: English
Subfield: Microbiology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,045
Funders: Wellcome Trust, Cancer Research UK, European Commission, National Institutes of Health, Directorate for Biological Sciences, Medical Research Council, Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, BrisSynBio, National Institute of Allergy and Infectious Diseases
Awards: MICA: Mechanistic understanding of cell wall biosynthesis to combat antimicrobial resistance, The role of hTRPA1 in Pain Sensation, BrisSynBio: Bristol Centre for Synthetic Biology, BBSRC IAA University of Oxford, Centre for structural analysis of complex biological systems, G3712868727, G396232211, G4494338184, European Gram Negative Antibacterial Engine, Defining the physiology and therapeutic potential of oxygenases as signalling enzymes., G621933505, Development and validation of new reagents and assays to exploit the final steps of peptidoglycan construction, G6712049296, G7045001909, A Mechanism Based Approach to Metallo beta-lactamase Inhibition
OpenAlex ID: W2970048441
